Kamila Romanowski, Silvia S Chiang, Sierra A Land, Marieke M van der Zalm, Jonathon R Campbell
{"title":"Tuberculosis-associated respiratory impairment and disability in children and adolescents: a systematic review.","authors":"Kamila Romanowski, Silvia S Chiang, Sierra A Land, Marieke M van der Zalm, Jonathon R Campbell","doi":"10.1016/j.eclinm.2025.103107","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>While the immediate effects of pulmonary tuberculosis are well-documented, respiratory impacts persisting beyond treatment, particularly in children and adolescents, are less understood. This systematic review aimed to evaluate the current evidence on tuberculosis-associated respiratory impairment and disability in children and adolescents following tuberculosis treatment.</p><p><strong>Methods: </strong>We searched MEDLINE, Embase, CENTRAL, Global Index Medicus, and preprints from January 1, 2004, to December 5, 2024, to identify studies enrolling children (0-9 years old) or adolescents (10-19 years old) who completed treatment for microbiologically confirmed or clinically diagnosed pulmonary tuberculosis. Eligible studies measured at least one tuberculosis-associated respiratory impairment or disability outcome. Data were analyzed descriptively and stratified into three age groups based on median age of tuberculosis diagnosis: <5 years, 5-10 years, and >10 years. This study was prospectively registered (PROSPERO CRD42024529906).</p><p><strong>Findings: </strong>We identified 117 studies reporting tuberculosis-associated respiratory impairment or disability outcomes. Of those, five met our inclusion criteria, as over 80% of the identified studies excluded children and adolescents. Following tuberculosis treatment, children and adolescents exhibited significant respiratory impairments. In children <5 years of age, impairment included reduced tidal volume and peak tidal expiratory flow. Among those 5-10 years, approximately 40% exhibited abnormal lung function post-treatment, increasing to 65% in adolescents >10 years. Disability was frequently reported, with 35-50% of children and adolescents experiencing respiratory symptoms and children <10 years showing reduced growth metrics and a diminished quality of life.</p><p><strong>Interpretation: </strong>Even after successful tuberculosis treatment, children and adolescents can experience respiratory impairments and disability that may reduce their quality of life, ability to participate in activities, and growth potential. The epidemiology and clinical manifestations of these impairments vary by age, reflecting distinct biological and behavioural differences. Future research should prioritize these younger populations to ensure their unique needs and challenges are adequately represented.</p><p><strong>Funding: </strong>The Robert E. Leet & Clara Guthrie Patterson Trust; Canadian Institutes of Health Research.</p>","PeriodicalId":11393,"journal":{"name":"EClinicalMedicine","volume":"81 ","pages":"103107"},"PeriodicalIF":10.0000,"publicationDate":"2025-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11872603/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"EClinicalMedicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.eclinm.2025.103107","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/3/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0
Abstract
Background: While the immediate effects of pulmonary tuberculosis are well-documented, respiratory impacts persisting beyond treatment, particularly in children and adolescents, are less understood. This systematic review aimed to evaluate the current evidence on tuberculosis-associated respiratory impairment and disability in children and adolescents following tuberculosis treatment.
Methods: We searched MEDLINE, Embase, CENTRAL, Global Index Medicus, and preprints from January 1, 2004, to December 5, 2024, to identify studies enrolling children (0-9 years old) or adolescents (10-19 years old) who completed treatment for microbiologically confirmed or clinically diagnosed pulmonary tuberculosis. Eligible studies measured at least one tuberculosis-associated respiratory impairment or disability outcome. Data were analyzed descriptively and stratified into three age groups based on median age of tuberculosis diagnosis: <5 years, 5-10 years, and >10 years. This study was prospectively registered (PROSPERO CRD42024529906).
Findings: We identified 117 studies reporting tuberculosis-associated respiratory impairment or disability outcomes. Of those, five met our inclusion criteria, as over 80% of the identified studies excluded children and adolescents. Following tuberculosis treatment, children and adolescents exhibited significant respiratory impairments. In children <5 years of age, impairment included reduced tidal volume and peak tidal expiratory flow. Among those 5-10 years, approximately 40% exhibited abnormal lung function post-treatment, increasing to 65% in adolescents >10 years. Disability was frequently reported, with 35-50% of children and adolescents experiencing respiratory symptoms and children <10 years showing reduced growth metrics and a diminished quality of life.
Interpretation: Even after successful tuberculosis treatment, children and adolescents can experience respiratory impairments and disability that may reduce their quality of life, ability to participate in activities, and growth potential. The epidemiology and clinical manifestations of these impairments vary by age, reflecting distinct biological and behavioural differences. Future research should prioritize these younger populations to ensure their unique needs and challenges are adequately represented.
Funding: The Robert E. Leet & Clara Guthrie Patterson Trust; Canadian Institutes of Health Research.
背景:虽然肺结核的直接影响有充分的文献记载,但治疗后持续的呼吸系统影响,特别是对儿童和青少年的影响,尚不清楚。本系统综述旨在评估儿童和青少年结核病治疗后结核病相关呼吸障碍和残疾的现有证据。方法:从2004年1月1日至2024年12月5日,我们检索MEDLINE、Embase、CENTRAL、Global Index Medicus和预印本,以确定纳入已完成微生物学确诊或临床诊断肺结核治疗的儿童(0-9岁)或青少年(10-19岁)的研究。符合条件的研究至少测量了一种与结核病相关的呼吸障碍或残疾结果。对数据进行描述性分析,并根据结核病诊断的中位年龄(10岁)分为三个年龄组。本研究已前瞻性注册(PROSPERO CRD42024529906)。研究结果:我们确定了117项报告结核病相关呼吸损伤或残疾结果的研究。其中5项符合我们的纳入标准,因为超过80%的研究排除了儿童和青少年。在接受结核病治疗后,儿童和青少年表现出明显的呼吸障碍。儿童10岁。解释:即使在结核病成功治疗后,儿童和青少年也可能出现呼吸障碍和残疾,这可能会降低他们的生活质量、参与活动的能力和成长潜力。这些损伤的流行病学和临床表现因年龄而异,反映出明显的生物学和行为学差异。未来的研究应优先考虑这些年轻人群,以确保他们独特的需求和挑战得到充分的体现。资助:Robert E. Leet & Clara Guthrie Patterson信托基金;加拿大卫生研究所。
期刊介绍:
eClinicalMedicine is a gold open-access clinical journal designed to support frontline health professionals in addressing the complex and rapid health transitions affecting societies globally. The journal aims to assist practitioners in overcoming healthcare challenges across diverse communities, spanning diagnosis, treatment, prevention, and health promotion. Integrating disciplines from various specialties and life stages, it seeks to enhance health systems as fundamental institutions within societies. With a forward-thinking approach, eClinicalMedicine aims to redefine the future of healthcare.